Kestra Medical CEO sells shares in two Nov. 18 trades
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kestra Medical Technologies, Ltd. (KMTS) director and President and Chief Executive Officer Brian Daniel Webster sold 11,715 common shares at a weighted average price of $28.2837 per share and 3,285 common shares at $29.0951 per share on November 18, 2026. Both sales were made pursuant to a Rule 10b5-1 trading plan adopted on July 21, 2026.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Shares F1, F2 | 11,715 | $28.2837 | $331K |
| Sale | Common Shares F1, F3 | 3,285 | $29.0951 | $96K |
Footnotes (3)
- F1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on July 21, 2026.
- F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $27.7927 to $28.7900. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
- F3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $28.8300 to $29.2950. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.